Navigation Links
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Date:5/15/2012

WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatments of breast cancer:

Dr. Kathy D. Miller, M.D.
Indiana University School of Medicine Melvin and Bren Simon Cancer Center
Department of Medicine, Division of Hematology and Oncology

Dr. Miller's career combines both laboratory and clinical research in breast cancer.  She has served as co-chair of the Hoosier Oncology Group Breast Committee since early 2002 and became co-chair of the Eastern Cooperative Oncology Group Breast Core Committee in 2010.  In these roles, she has worked with community oncologists to develop trials that combine clinical and biologic endpoints, yet remain feasible in non-academic settings.  Dr. Miller first honed her ability to coordinate multi-center trials as principal investigator for E2100, the first phase III trial to confirm the benefits of anti-angiogenic therapy in patients with metastatic breast cancer.  Dr. Miller currently leads E5103, an international phase III trial investigating anti-angiogenic therapy in the adjuvant setting.

Dr. Miller received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore, MD.  Dr. Miller completed internal medicine training at Hopkins, then returned to her native Midwest for fellowship training in hematology and oncology at Indiana University, serving as Chief Fellow in 1997.  She returned to Indiana University in 1999, attaining the rank of Associate Professor and Sheila D Ward Scholar in 2005.

Dr. Hope S. Rugo, M.D. 
University of Calif
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014   BioTE Medical ... using natural, bio-identical hormone pellets, today announced the ... to the company.   Dr. Rouzier is joining the ...     Dr. Rouzier was residency trained ... and is a board certified emergency physician still ...
(Date:7/22/2014)... 2014 Rice Lake Weighing ... 2014 NCSL International Workshop and Symposium July 28-31 ... CONDEC pressure instrumentation, OIML M1 weights, precision lab ... customized sets, Essential Weights™. , NCSL International was ... in solving the common problems faced by measurement ...
(Date:7/22/2014)... -- Neogen Corporation (NASDAQ: NEOG ) announced today ... May 31, increased 19% from the previous year to ... the prior year,s $27,190,000. Adjusted for a 3-for-2 stock ... the current year were $0.76, compared to $0.75 a ... 2014 fiscal year established new all-time highs for the ...
(Date:7/22/2014)... SHENZHEN, China , July 22, 2014 /PRNewswire/ ... a subsidiary of BGI, the world,s largest genomics ... new human whole exome sequencing service based on ... includes in-depth bioinformatics analysis and SNP validation, and ... 2014. Complete Genomics, highly regarded ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing ... oils in plant seeds, provides an update ... program. In December 2008, SemBioSys announced that ... license rights to SemBioSys, proprietary plant-produced recombinant ...
... efficiency in imaging IT.CHICAGO, April 1 Siemens ... www.siemens.com/healthcare ) ... portals, innovative applications, and intelligent information systems for radiology ... Management Systems Society (HIMSS) 2009 Annual Conference and Exhibition ...
... China, April 1 /PRNewswire-Asia-FirstCall/ -- Kun Run,Biotechnology, Inc., (OTC ... focuses on manufacture and sales of peptides and,peptide-based drugs, ... 31, 2008. , Revenues for ... an,increase of $4.1 million, or 56% over revenues for ...
Cached Biology Technology:SemBioSys provides update on insulin program 2SemBioSys provides update on insulin program 3Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009 2Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009 3Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009 4Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009 5Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 2Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 3Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 4Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 5Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 6Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 7Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 8
(Date:7/22/2014)... from the National Institute of Standards and Technology ... a dramatically improved technique for analyzing biological cells ... The new NIST technique is an advanced form ... one that delivers signals that are 10,000 times ... 100 times stronger than obtained from comparable "coherent ...
(Date:7/22/2014)... disease causing agents, some viruses can perform crucial ... the world we live in today, according to ... Microbiology. , "Viruses participate in essential Earth processes ... from contributing to biogeochemical cycles, shaping the atmospheric ... Roossinck of Pennsylvania State University, a member of ...
(Date:7/22/2014)... offer much promise for treating damaged organs and tissues, ... poor, limiting their effectiveness. New methods are being developed ... therapeutic function after transplantation, as described in a Review ... journal from Mary Ann Liebert, Inc., publishers. The article ... website . , In the article ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Calif. -- November 9, 2012 -- The Society of Environmental ... to Kevin Brix at the its 33rd Annual Meeting, November ... recently completed his Ph.D. at the Rosenstiel School of Marine ... has already made exceptional contributions to the understanding of fate ...
... November 2012: Scientists at the University of Liverpool ... the English Channel have the potential to affect the ... Channel Islands. The study by the University of ... Trust, funded by the Alderney Commission for Renewable Energy, ...
... International African Vaccinology Conference, Cape Town, South AfricaResults from ... in the New England Journal of Medicine , ... protect African infants against malaria. When compared to immunization ... first vaccination) vaccinated with RTS,S had one-third fewer episodes ...
Cached Biology News:SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2Gannets could be affected by offshore energy developments 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
GLP-1 (HYB 147-12)...
... gene in baculoviral expression vector, transfection ... purification of ten clones, generation of ... clone, protein expression and tag purification ... yield and timeline: 1-4 mg of ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Biology Products: